Recently, Demis Hassabis, one of the founders of Google, revealed in an interview that his company Isomorphic Labs plans to begin a clinical trial for a drug developed using artificial intelligence (AI) by the end of the year. This news has drawn significant attention, particularly regarding its potential applications in oncology, cardiovascular diseases, and neurodegenerative disorders. Image credit: Image generated by AI, image licensed from Midjourney Isomorphic.

AI drug development company Genesis Therapeutics recently announced that it has secured additional investment from Nvidia's venture capital arm, NVentures, though the specific amount remains undisclosed. This move marks a further deepening of the collaboration between the two parties, aimed at accelerating the development of Genesis's AI platform GEMS (Genesis Exploration of Molecular Space), which focuses on utilizing physics-based AI for structure-driven drug design.